COMMUNIQUÉS West-GlobeNewswire
-
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
14/09/2026 -
Unlocking the Growth - Invitation to BioPorto’s investor meeting on Oct 7
14/09/2026 -
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
14/09/2026 -
New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System
14/09/2026 -
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
14/09/2026 -
Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical Operations
14/09/2026 -
Communiqué de presse : Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour des médicaments matures
14/09/2026 -
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
14/09/2026 -
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
14/09/2026 -
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
14/09/2026 -
Novo Nordisk A/S - share repurchase programme
14/09/2026 -
SafeSpace Global Announces First K-12 School Installation of Its AI-Powered Physical Safety Platform
14/09/2026 -
Catalyst MedTech Helps Imaging Providers See What’s Next in Nuclear Cardiology at ASNC 2026
14/09/2026 -
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
14/09/2026 -
Children’s National receives $56.25 million Pediatric Prevention Network award
14/09/2026 -
Bio Usawa and Axmed Partner to Expand Access to Affordable Biologic Medicines Across Africa
14/09/2026 -
Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
14/09/2026 -
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
14/09/2026 -
Etienna Bio Completes FDA INTERACT Meeting for ETB-001
14/09/2026
Pages